| 2024 |
Dr. Tobias Jaud |
The maze of extractables and leachables - Regulatory risk assessment of β-Glucans |
|
|
| 2024 |
Jessica Jeschke |
Regulatory and Scientific Strategies to Combat Antimicrobial Resistance in the EU |
|
|
| 2024 |
Eva Kreßner |
Finding a balance between the need for comprehensive transparency in clinical trials and the protection of commercially confidential information in today’s regulatory environment |
|
|
| 2024 |
Dr. Sabine Küppers |
Development of Tissue Engineered Products in the EU - Will the European Commission’s and EMA's Action Plan on Advanced Therapy Medicinal Products make the difference? |
|
|
| 2024 |
Michael Link |
Comparative Analysis of Evaluation and Reimbursement Pathways for Digital Health Applications in Germany, France, and Belgium - Current Status and Outlook for the EU |
|
|
| 2024 |
Guy Noel Mouoffo |
Enhancing Regulatory Reliance practices in international cooperation: A Focus on Information Sharing |
|
|
| 2024 |
Dr. Gilbert Müller |
Drug Name (Un-)Likeness - Methods and Strategies to Find an Approvable Drug Name |
|
|
| 2024 |
Dr. Thilo Nölke |
Veterinary Regulatory Measures to Counteract Antimicrobial Resistance in Germany and on EU-Level |
|
|
| 2024 |
Dr. Mahsa Rahbari |
Benefits of Structured Content Management for Labeling Compliance in the Pharmaceutical Industry |
|
|
| 2024 |
Dr. Isabel Ramtohul |
Impact assessment of the proposed Pharma Legislation of the European Union on a pharmaceutical industry portfolio with focus on Regulatory Data Protection and Orphan Market Exclusivity and associated conditions |
|
|
| 2024 |
Alexander Reichenbach |
Regulatory considerations for CMC development of platform based mRNA vaccines |
|
|
| 2024 |
Julia Schlischewski |
Medizinisches Cannabis in Deutschland seit 2017 – Eine kritische Analyse der bisherigen Entwicklung im Vergleich mit der Regulierung in Kanada |
|
|
| 2024 |
Bich Nguyet Seipel |
The Future of Plasma-Derived Medicinal Products in the European Union under the European Commission’s Proposed Regulation on Substances of Human Origin: An Analysis of the Amendments and Their Impact |
|
|
| 2024 |
Marina Semakov |
Artificial Intelligence in Regulatory Affairs CMC - Chances and Challenges |
|
|
| 2024 |
Dr. Gianna Thomsen |
Development of a regulatory toolbox for the approval procedure for medicinal products for human use |
|
|
| 2024 |
Dr. Felix Wolf |
Environmental challenges for medicinal products arising from the proposed pharma legislation of the European Union and consequential implications for different EU stakeholders |
|
|
| 2023 |
Dr. Irina Anusca |
Clinical Evaluation of light-cure resin modified Dental Composite according to MDR 745/2017 |
|
|
| 2023 |
Deanna Yuching Balakhonova |
An Overview of Current Regulatory Environment Regarding Artificial Intelligent (AI)-Based Medical Device Software (MDSW) in EU |
|
|
| 2023 |
Justin-Christopher Bell |
Regulatory Informatics and Labelling Management Systems - Recent Developments and Description of a State-of-the-Art Labelling Management Software in the Pharmaceutical Industry |
|
|
| 2023 |
Katharina Böhm |
Clinical Trials Regulations (CTR) – An analysis of the first clinical trial applications in the public portal of the Clinical Trials Information System (CTIS) |
|
|
